Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.
The results of an open-label pilot study comparing combinations of anti-PD1 (nivolumab) alone, or in combination with either anti-CTLA-4 (ipilimumab...
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC),...
A study of racial disparities in health-related quality of life of colorectal cancer patients revealed among several findings, that Hispanics...
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
Based on their findings, the researchers launched a clinical trial for stage IV prostate cancer in March combining two drugs that target separate...
The 31st annual Polo on the Prairie, a U.S. Polo Association-sanctioned event benefiting cancer research and patient care programs at The...
The University of Texas MD Anderson Cancer Center brings Jim Ray, Ph.D., head of Neuroscience, to Dallas on Thursday, April 20, to lead two...
University of Texas System Chancellor William H. McRaven announced today the appointment of Marshall E. Hicks, M.D., as interim president...
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment...
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts...
Ronald A. DePinho M.D., president of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven...
When Dr. Ron DePinho was named president of The University of Texas MD Anderson Cancer Center by the Board of Regents in 2011, ...
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy...
Cancer prevention specialists from The University of Texas MD Anderson Cancer Center will provide skin cancer screenings free to the public...
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard...
It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint...
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid...